Kochenderfer: ‘I think the main focus of the CAR field will be autologous cells…’

John Carroll

Yesterday there was a brief, digital dust-up on Twitter over an abstract circulating online on a CAR-T study undertaken from the NCI's James , one of the top scientists in the . His team tracked remissions in 8 of 20 patients using allogeneic T reengineered to attack cancer. Some in the investor community interpreted the use of "allogeneic" as an "off-the-shelf" approach similar to what Cellectis has been at work on.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS